Cambridge, Mass. biopharmaceutical company, Genocea Biosciences, Inc., announced this week positive 12 month efficacy data from its Phase 2 dose optimization trial evaluating GEN-003 for the treatment...

By

Genocea Biosciences, Inc. , a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, yesterday presented data from a Phase 1 study of GEN-004, an investigational vaccine designed...